Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome

Francis, Glenn, Beadle, Geoffrey, Thomas, S., Mengersen, K. and Stein, Sandra (2006) Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome. Pathology, 38 5: 391-398. doi:10.1080/00313020600922488

Related Publications and Datasets
Author Francis, Glenn
Beadle, Geoffrey
Thomas, S.
Mengersen, K.
Stein, Sandra
Title Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome
Journal name Pathology   Check publisher's open access policy
ISSN 0031-3025
Publication date 2006-01-01
Sub-type Article (original research)
DOI 10.1080/00313020600922488
Open Access Status Not Open Access
Volume 38
Issue 5
Start page 391
End page 398
Total pages 8
Publisher Royal College of Pathologists of Australasia
Language eng
Subject CX
321020 Pathology
730108 Cancer and related disorders
Abstract Aim: HER-2/neu amplification occurs in 15-25% of breast carcinomas. This oncogene, also referred to as c-erbB-2, encodes a transmembrane tyrosine kinase receptor belonging to the epidermal growth factor receptor family. HER-2 over-expression is reported to be associated with a poor prognosis in breast carcinoma patients and in some studies is associated with a poorer response to anti-oestrogen therapy. These patients are less likely to benefit from CMF (cyclophosphamide, methotrexate, fluorouracil)-based chemotherapy compared with anthracycline-based chemotherapy. The aim of this study was to evaluate breast carcinomas to determine hormone receptor status and if there is a difference in breast cancer specific survival for HER-2 positive patients. Methods: A total of 591 breast carcinomas were evaluated using immunohistochemistry (IHC) for oestrogen receptor (ERp), progesterone receptor (PRp) and three different HER2 antibodies (CB11, A0485 and TAB250). Percentage of tumour cells and intensity of staining for ERp were evaluated using a semiquantitative method. Results: Of the 591 tumours, 91 (15.4%) showed 3+ membrane staining for HER-2 with one or more antibodies. Of these 91 tumours, 41 (45.1%) were ERp+/ PRp+, seven (7.7%) were ERp+/PR-, six (6.6%) were ERp-/PRp+ and 37 (40.7%) were ERp-/PR-. Of HER-2 positive tumours, 5.5% showed > 80% 3+ staining for ERp compared with 31.8% of 0-2+ HER-2 tumours; 24.2% of HER-2-positive tumours showed 60% or more cells with 2+ or 3+ staining for ERp. Treatment data were available for 209 patients and no difference was observed in breast cancer specific survival (BCSS) with HER-2 status and tamoxifen. Conclusion: Oestrogen receptor status cannot be used to select tumours for evaluation of HER-2 status, and oestrogen and progesterone receptor positivity does not preclude a positive HER-2 status. There is a higher proportion of ERp negative tumours associated with HER-2 positivity, however, more than 20% of HER-2 positive tumours show moderate or strong staining for ERp. HER-2 positive patients in this study did not show an adverse BCSS with tamoxifen treatment unlike some previous studies.
Keyword Pathology
Surgical Pathology
Cancer And Carcinoma
Growth-factor Receptor
Endocrine Therapy
Tamoxifen Resistance
Hormone Receptors
Q-Index Code CX

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 18 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 18 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 21:00:27 EST